Tuesday, December 13, 2022
Semler Scientific, Inc., a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today announced an up to $5.0 million investment in privately-held Monarch Medical Technologies, LLC (Monarch) through the purchase of a senior secured convertible promissory note. Repayment of the note is secured by a first priority interest in all of Monarch's assets.
Monarch is a digital health company whose proprietary EndoTool® Glucose Management System offers a technology-enabled approach to inpatient glycemic management. The software-as-a-service solution is FDA 510(k) cleared, patent protected and installed at more than 100 health systems across the United States.
The investment in Monarch complements Semler Scientific's offering of Insulin Insights™, a glycemic management software application that healthcare providers can use to optimize outpatient insulin dosing for persons with diabetes.
"We are excited to add a second company in the diabetes management space to our network," said Doug Murphy-Chutorian, M.D., chief executive officer of Semler Scientific. "We believe Monarch has a superior software solution to address customers' concerns about nursing shortages and new CMS quality measures for hypoglycemia and hyperglycemia in the inpatient setting."
